Table 2.
Annual cost inputs used in the study [by Chinese yuan (¥) and USD ($)]
| RMS management cost by EDSS score | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |
| Direct medical cost | ¥0 ($0) |
¥2019 ($304) |
¥9736 ($1465) |
¥17,453 ($2625) |
¥25,169 ($3786) |
¥32,886 ($4947) |
¥39,187 ($5895) |
¥45,015 ($6772) |
¥50,844 ($7648) |
¥56,672 ($8525) |
| Cost of managing relapse | |||
|---|---|---|---|
| Leading to hospitalization | ¥16,865 ($2537) | ||
| Not leading to hospitalization | ¥3685 ($554) | ||
| Treatment | Treatment acquisition cost | Administration cost | Monitoring costs | |
|---|---|---|---|---|
| Year 1 | Year 2+ | |||
| Teriflunomide 14 mg | ¥93,816 ($14,113) | ¥0 ($0) | ¥1603 ($241) | ¥1101 ($166) |
| Interferon beta-1b 250 mcg | ¥106,200 ($15,976) | ¥4.5 ($0.7) | ¥1501 ($226) | ¥1101 ($166) |
Average exchange rate for 2018 of US$1 = ¥6.6476 was used for conversion
In this table, unit cost in China was based on the China Health Insurance Research Association (CHIRA) database, resource use estimates were obtained from the Chinese key opinion leaders survey
Please refer to Supplemental Material for a detailed list of references
EDSS expanded disability status scale, RMS relapsing multiple sclerosis